Abiraterone

Department of Health and Social Care written question – answered at on 28 October 2025.

Alert me about debates like this

Photo of Danny Beales Danny Beales Labour, Uxbridge and South Ruislip

To ask the Secretary of State for Health and Social Care, whether NHS England has approved any drugs with a higher incremental cost-effectiveness ratio than abiraterone for high-risk, non-metastatic prostate cancer in the last five years.

Photo of Danny Beales Danny Beales Labour, Uxbridge and South Ruislip

To ask the Secretary of State for Health and Social Care, what information his Department holds on the estimate made by (a) NHS England, (b) NHS Wales and (c) NHS Scotland of the incremental cost-effectiveness ratio for abiraterone in high-risk, non-metastatic prostate cancer.

Photo of Zubir Ahmed Zubir Ahmed The Parliamentary Under-Secretary for Health and Social Care

NHS England has not calculated the incremental cost-effectiveness ratio for any policy proposition because NHS England uses a relative prioritisation process for policy propositions that require funding in line with the published NHS England Specialised Commissioning Service Development Policy, a copy of which is attached.

Additional Document (pdf, 293.9KB)

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.

Secretary of State

Secretary of State was originally the title given to the two officials who conducted the Royal Correspondence under Elizabeth I. Now it is the title held by some of the more important Government Ministers, for example the Secretary of State for Foreign Affairs.